debt_leverage_profile
Effectively zero debt; cash-funded clinical-stage biotech with ~$150M+ cash runway, no meaningful leverage ratio applicable
Inferred
Agent_Inference
interest_rate_sensitivity
Minimal direct impact; rising rates reduce treasury yield uplift on cash reserves but company carries no floating-rate debt
Inferred
Agent_Inference
geopolitical_supply_exposure
Low intensity; China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
supply_chain_dependency
1) API sourcing from contract manufacturers (CMOs) concentrated in India/China; 2) specialty reagent suppliers in EU/US facing geopolitical tariff risk
Inferred
Agent_Inference
international_expansion_readiness
No international commercial revenue; USD-denominated operations only; no material sovereign currency devaluation exposure currently
Inferred
Agent_Inference
geographic_footprint
Operations entirely US-based (Watertown, MA); no top-three international revenue markets exist; currency devaluation exposure is negligible
Inferred
Agent_Inference
commodity_exposure_profile
Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.
Medium
GICS-commodity-overlay-v1
vendor_lock_dependency_score
Single CRO/CMO dependency likely exceeds 30% of operational input cost; proteomics platform relies on specialized mass spectrometry vendors with limited substitutes
Inferred
Agent_Inference
business_model_type_primary
Clinical-stage biopharma; no commercial product revenue; cloud disruption would delay R&D workflows but not immediately destroy revenue-generating operations
Inferred
Agent_Inference
business_model_type_secondary
Precision oncology platform company; AP3 proteomics-based patient selection is core; data infrastructure disruption would impair biomarker analysis pipelines significantly
Inferred
Agent_Inference
switching_cost_profile
High API coupling risk to proprietary AP3 proteomics platform; external bioinformatics pipelines and CRO integrations create meaningful switching friction
Inferred
Agent_Inference
howey_test_risk_index
Low Howey risk; revenue model is milestone/licensing from pharma partnerships and future drug sales, not investment contracts; standard biopharma structure
Inferred
Agent_Inference
regulatory_burden_tier
Very High
Medium
GICS-regulatory-overlay-v1
data_sovereignty_risk
Limited GDPR/CCPA exposure currently; clinical trial patient data governed by HIPAA/ICH-GCP; EU trial expansion would trigger GDPR obligations
Inferred
Agent_Inference
antitrust_exposure_flag
Negligible antitrust risk; pre-revenue clinical stage company with no market share; proprietary biomarker platform creates no horizontal dominance concern
Inferred
Agent_Inference
regulatory_exposure_profile
Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.
Medium
GICS-regulatory-overlay-v1
revenue_model_type
~100% non-recurring; revenue consists of collaboration milestones and grants (e.g., Merck partnership); no subscription or retainer revenue stream
Inferred
Agent_Inference
monetization_vector
Milestone-based collaboration payments plus future royalties/drug sales; near-term revenue entirely contingent on clinical trial outcomes and partner triggers
Inferred
Agent_Inference
pricing_architecture
No commercial pricing architecture yet; future oncology drug pricing will follow specialty/rare-cancer premium model (~$150K–$300K/year per patient estimated)
Inferred
Agent_Inference
pricing_power_rating
Potentially high if AP3-selected patient response rates validate; precision oncology companion diagnostics command premium pricing with payer acceptance
Inferred
Agent_Inference
target_gross_margin_bracket
Target gross margin 80–90%+ at commercial stage (typical oncology drug); current stage has no product gross margin
Inferred
Agent_Inference
churn_vulnerability_index
No free-rider leakage problem; proprietary AP3 platform and companion diagnostic create high exclusivity; no open-access data model
Inferred
Agent_Inference
headcount_cost_structure
Revenue growth sublinear to headcount at commercial stage; clinical/platform phase is headcount-intensive R&D; commercialization could leverage lean sales force
Inferred
Agent_Inference
marginal_cost_of_growth
Marginal cost of growth currently high (clinical trials dominate opex); at commercial launch, incremental revenue per rep addition improves significantly
Inferred
Agent_Inference
franchise_compliance_risk
Not applicable; company does not operate a franchise model
Inferred
Agent_Inference
customer_acquisition_metric
At 10x scale, CAC economics depend on oncologist adoption rates and companion Dx reimbursement; current unit economics unproven pre-commercialization
Inferred
Agent_Inference
network_effect_present
Weak direct network effects; indirect data network effect possible as AP3 proteomics database grows with more patient samples, improving predictive accuracy
Inferred
Agent_Inference
asset_efficiency_ratio
-60.0% Return on Assets (Negative equity)
High
SEC-XBRL
recession_resistance_tier
Moderate-high recession resistance; oncology treatments are non-discretionary; however, clinical-stage funding is vulnerable to risk-off capital markets
Inferred
Agent_Inference
customer_segment_primary
Pharmaceutical/biotech partners (e.g., Merck) as near-term revenue customers; oncologists and cancer patients as end-users at commercialization
Inferred
Agent_Inference
customer_segment_secondary
Hospital oncology centers and academic cancer centers as clinical trial sites and future institutional prescribers
Inferred
Agent_Inference
characteristic_occupations
["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]
High
SOC-2018/GICS-overlay
agent_automatable_labor_share
0.32 (HIL — ~32% of characteristic roles agent-automatable)
Medium
SOC-2018 + agentic-exposure-v1
capital_expenditure_profile
Capital allocated toward future-state: AP3 proteomics platform buildout and clinical trial execution; minimal legacy infrastructure reallocation needed
Inferred
Agent_Inference
sec_cik
0001781174
High
SEC-EDGAR
ticker
ACRV
High
SEC-EDGAR